GeneDx To Present Four Research Sessions At The 2025 National Society Of Genetic Counselors Annual Meeting, Showcasing Advances Powered By Its Genedx Infinity Platform

Powered by GeneDx Infinity™ with unparalleled scale and diversity, GeneDx fuels breakthrough scientific research and delivers the most precise rare disease diagnosis for patients and families

GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.

"GeneDx is at the forefront of genomic discovery, accelerating gene-disease insights, advancing long-read sequencing, and improving access so more families can reach answers sooner," said Britt Johnson, PhD, FACMG, SVP of Medical Affairs at GeneDx. "Powered by the scale and diversity of GeneDx Infinity™ and the deep expertise of our team, we are pioneering innovations that elevate diagnostic accuracy, deepen scientific understanding, and bring the full potential of precision medicine to patients and families around the world."

At NSGC, GeneDx will showcase innovation and clinical breakthroughs powered by GeneDx Infinity™, the largest rare disease dataset. The company will highlight Infinity's role in identifying novel gene-disease discoveries, which enable GeneDx to offer clear answers for clinicians and earlier, more accurate diagnoses for patients and families. Additionally, GeneDx is showcasing how data generated from genomic testing drives progress and impact across the healthcare ecosystem, from patients and advocacy groups to clinical laboratories to biopharma companies and beyond. GeneDx will also highlight data supporting the potential of long read sequencing and work being done on reimbursement and access.